Predicting tumour response

Cancer Imaging

Volumn 13, Issue 3, 2013, Pages 381-390

  Kyle, Samuel D ^a,b   Phillip Law, W ^a,b   Miles, Kenneth A ^a,c  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Cancer; Imaging; Predict; Response; Tumour

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; HYPOXIA INDUCIBLE FACTOR 1; IODINE 123; LIPOCORTIN 5; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; OLIGONUCLEOTIDE; PENTETREOTIDE IN 111; RADIOISOTOPE; TETRAXETAN; THYROTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIFFERENTIATED THYROID CANCER; DIFFUSION WEIGHTED IMAGING; ESOPHAGUS CANCER; GENETIC MARKER; HEAD AND NECK CANCER; HUMAN; HYPOXIA; INDIVIDUALIZATION; LUNG NON SMALL CELL CANCER; LYMPHOMA; MULTIMODALITY CANCER THERAPY; NECROSIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PERFUSION; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOISOTOPE THERAPY; RECTUM CANCER; REVIEW; SARCOMA; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME; UTERINE CERVIX CANCER;

ANGIOGENESIS INHIBITORS; CELL HYPOXIA; FLUORODEOXYGLUCOSE F18; GENETIC MARKERS; HUMANS; NECROSIS; NEOPLASMS; RADIOISOTOPES;

EID: 84885630406     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2013.9039     Document Type: Review

References (75)

1. Weber WA. Assessing tumor response to therapy. J Nucl Med 2009; 50(Suppl 1): 1S-10S. doi:10.2967/jnumed.108.057174. PMid:19380403.
2. Sullivan DC, Gatsonis C. Response to treatment series: part 1 and introduction, measuring tumor response-challenges in the era of molecular medicine. AJR Am J Roentgenol 2011; 197: 15-17 doi:10.2214/AJR.11.7083. PMid:21701005.
3. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247 doi:10.1016/j.ejca.2008.10.026. PMid:19097774.
4. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005; 7: 307-311 PMid:15946591. (Pubitemid 41149677)
5. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586 doi:10.1200/jco.2006.09.2403. PMid:17242396. (Pubitemid 350002966)
6. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-1523 doi:10.1093/annonc/mdi272. PMid:15980161. (Pubitemid 41222425)
7. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59 doi:10.1182/blood-2005-06-2252. PMid:16150944. (Pubitemid 43053523)
8. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2008; 49: 13-21 doi:10.2967/jnumed.107.039867. PMid:18077527.
9. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91: 522-529 PMid:16585017.
10. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652-4661 doi:10.1200/jco.2005.01.891. PMid:15837965. (Pubitemid 46224067)
11. Kasenda B, Haug V, Schorb E, et al. 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med 2013; 54: 184-191 doi:10.2967/jnumed.112.108654. PMid:23249539.
12. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065 PMid:11408502. (Pubitemid 32565444)
13. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692-4698 doi:10.1200/jco.2006.06.7801. PMid:16966684. (Pubitemid 46646244)
14. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22: 900-908 doi:10.1200/jco.2004.07.122. PMid:14990646. (Pubitemid 41103602)
15. Malik V, Lucey JA, Duffy GJ, et al. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med 2010; 51: 1863-1869 doi:10.2967/jnumed.110.079566. PMid:21078796.
16. van Heijl M, Omloo JM, van Berge Henegouwen MI, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 2011; 253: 56-63 doi:10.1097/SLA.0b013e3181f66596. PMid:21233607.
17. de Langen AJ, Klabbers B, Lubberink M, et al. Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 2009; 36: 389-395 doi:10.1007/s00259-008-0960-5. PMid:18931838.
18. Contractor KB, Kenny LM, Stebbing J, et al. [18F]-3′Deoxy-3′- fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res 2011; 17: 7664-7672 doi:10.1158/1078-0432.ccr-11- 0783. PMid:22028493.
19. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007; 34: 1339-1347 doi:10.1007/s00259-007-0379-4. PMid:17333178. (Pubitemid 47312585)
20. Dehdashti F, Grigsby PW, Myerson RJ, Nalbantoglu I, Ma C, Siegel BA. Positron emission tomography with [(18)F]-3′-deoxy-3′fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol 2013; 15: 106-113 doi:10.1007/s11307-012-0566-y. PMid:22684813.
21. Kartachova M, van Zandwijk N, Burgers S, van Tinteren H, Verheij M, Valdes Olmos RA. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol 2007; 25: 2534-2539 doi:10.1200/jco.2006.10.1337. PMid:17577031. (Pubitemid 47041226)
22. Rottey S, Slegers G, Van Belle S, Goethals I, Van de Wiele C. Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med 2006; 47: 1813-1818 PMid:17079815. (Pubitemid 47545004)
23. Danishad KK, Sharma U, Sah RG, Seenu V, Parshad R, Jagannathan NR. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed 2010; 23: 233-241 doi:10.1002/nbm.1436. PMid:20175134.
24. Sharma U, Baek HM, Su MY, Jagannathan NR. In vivo 1H MRS in the assessment of the therapeutic response of breast cancer patients. NMR Biomed 2011; 24: 700-711 doi:10.1002/nbm.1654. PMid:21793075.
25. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008; 14: 6580-6589 doi:10.1158/1078-0432.CCR-07-4310. PMid:18927299.
26. Padhani AR, Liu G, Koh D-M, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125 doi:10.1593/neo.81328.
27. Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009; 15: 986-994 doi:10.1158/1078-0432.CCR-08-1287. PMid:19188170.
28. Theilmann RJ, Borders R, Trouard TP, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004; 6: 831-837 doi:10.1593/neo.03343. PMid:15720810. (Pubitemid 40041502)
29. Luster MF, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1941-1959
30. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002; 43: 1188-1200
31. Robbins RJ, Schlumberger MJ. The evolving role of 131-I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005; 46(Suppl): 28-47
32. Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med 2012; 53: 1633-1651 doi:10.2967/jnumed.112.105148. PMid:22787108.
33. Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40: 800-816 doi:10.1007/s00259-012-2330-6. PMid:23389427.
34. Bomanji JB, Papathanasiou ND. 111-In-DTPA-octreotide (Octreoscan), 131-I-MIBG and other agents for radionuclide therapy of NETs. Eur J Nucl Med Mol Imaging 2012; 39(Suppl 1): S113-125 doi:10.1007/s00259-011-2013-8. PMid:22388626.
35. Patel N, Harris AL, Gleeson FV, Vallis KA. Clinical imaging of tumor angiogenesis. Future Oncol 2012; 8: 1443-1459
36. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995 doi:10.1158/0008-5472.can-06-0191. PMid:16618717.
37. Mu XL, Li LY, Zhang XT, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 4289-4294 doi:10.1158/1078-0432.ccr-04-2506. PMid:15958609. (Pubitemid 40825615)
38. Watanabe T, Kobunai T, Yamamoto Y, et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 2011; 54: 1170-1178 doi:10.1097/DCR. 0b013e31821d37a3. PMid:21825899.
39. Bossard C, Kury S, Jamet P, et al. Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas. J Clin Pathol 2012; 65: 466-469 doi:10.1136/jclinpath-2011-200608. PMid:22259183.
40. Sundstrom M, Edlund K, Lindell M, et al. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer 2010; 10: 660. doi:10.1186/1471-2407-10-660. PMid:21122130.
41. Roivainen A, Tolvanen T, Salomaki S, et al. 68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med 2004; 45: 347-355 PMid:14960659. (Pubitemid 47618660)
42. Ganeshan B, Miles K, Ziauddin Z, Engledow A, Rodriguez-Justo M, Groves A. Identification of KRAS mutation in colorectal cancer by multi-parametric PET-CT. International Cancer Imaging Society 2012.
43. Garcia-Figueiras R, Goh VJ, Padhani AR, et al. CT perfusion in oncologic imaging: a useful tool? AJR Am J Roentgenol 2013; 200: 8-19 doi:10.2214/AJR.11. 8476. PMid:23255736.
44. Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 2007; 244: 486-493 (Pubitemid 47080881)
45. Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 2009; 193: 1090-1096 doi:10.2214/AJR.08. 1367. PMid:19770333.
46. Bisdas S, Rumboldt Z, Wagenblast J, et al. Response and progression-free survival in oropharynx squamous cell carcinoma assessed by pretreatment perfusion CT: comparison with tumor volume measurements. AJNR Am J Neuroradiol 2009; 30: 793-799 doi:10.3174/ajnr.A1449. PMid:19351906.
47. Zhang Z, Zhu J, Cai G, et al. Prediction of tumor response with CT perfusion of neoadjuvant chemoradiation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010; 78: S323.
48. Zahra MA, Tan LT, Priest AN, et al. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 2009; 74: 766-773 doi:10.1016/j.ijrobp.2008.08.023. PMid:19019563.
49. Mees G, Dierckx R, Vangestel C, Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009; 36: 1674-1686 doi:10.1007/s00259-009-1195-9. PMid:19565239.
50. Chitneni SK, Palmer GM, Zalutsky MR, Dewhirst MW. Molecular imaging of hypoxia. J Nucl Med 2011; 52: 165-168 doi:10.2967/jnumed.110.075663. PMid:21233176.
51. Eshmann S, Paulsen F, Matthias R, Dittman H. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in nonsmall cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253-260 (Pubitemid 43073432)
52. Hugonnet F, Fournier L, Medioni J, et al. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med 2011; 52: 1048-1055 doi:10.2967/jnumed.110.084517. PMid:21680694.
53. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of 18F-FDG and 18F-MISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006; 80: 151-156 doi:10.1016/j.radonc.2006.07.033. PMid:16920211. (Pubitemid 44301544)
54. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003; 30: 844-850 doi:10.1007/s00259-003-1130-4. PMid:12692685. (Pubitemid 36734203)
55. Dietz DW, Dehdashti F, Grigsby PW, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008; 51: 1641-1648 doi:10.1007/s10350-008-9420-3. PMid:18682881.
56. Minagawa Y, Shizukuishi K, Koike I, et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med 2011; 25: 339-345 doi:10.1007/s12149-011-0471-5. PMid:21327756.
57. Davnall F, Yip CS, Ljungqvist G, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging 2012; 3: 573-589 doi:10.1007/s13244-012-0196-6. PMid:23093486.
58. Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA. Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology 2013; 266: 326-336 doi:10.1148/radiol.12112428. PMid:23169792.
59. Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, Miles KA. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 2011; 261: 165-171 doi:10.1148/radiol.11110264. PMid:21813743.
60. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet. 2002; 360: 307-308 (Pubitemid 34874724)
61. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology 2010; 256: 348-364
62. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004; 59: 1295-1300 doi:10.1016/j.ijrobp.2003.12.039. PMid:15275712. (Pubitemid 38954050)
63. Kato H, Fukuchi M, Miyazaki T, et al. Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography. Anticancer Res 2007; 27: 2627-2633 PMid:17695425. (Pubitemid 47227975)
64. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on(18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17: 3201-3206 PMid:10506619. (Pubitemid 29470652)
65. Miles KA, Williams RE. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 2008; 8: 81-86 doi:10.1102/1470-7330.2008.0011. PMid:18390391. (Pubitemid 351517291)
66. Mankoff DA, Dunnwald LK, Partridge SC, Specht JM. Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res 2009; 15: 5294-5296 doi:10.1158/1078-0432.CCR-09-1448. PMid:19706819.
67. Komar G, Kauhanen S, Liukko K, et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009; 15: 5511-5517 doi:10.1158/1078-0432.CCR-09-0414. PMid:19706808.
68. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK. Blood flow and metabolism in locally advanced breast cancer: relationships to response to therapy. J Nucl Med 2002; 43: 500-509 (Pubitemid 34286345)
69. Mohan HK, Miles KA. Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med 2009; 50: 376-381 doi:10.2967/jnumed.108.055988. PMid:19223414.
70. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF. Functional imaging of multidrug-resistant p-glycoprotein with an organotechnetium complex. Cancer Res 1993; 73: 977-984 (Pubitemid 23087894)
71. Burak Z, Moretti J-L, Ersoy Ö, et al. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med 2003; 44: 1394-1401 (Pubitemid 39663350)
72. Fonti R, Del Vecchio S, Zannetti A, et al. Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma. Cancer Biother Radiopharm 2004; 19: 165-170 doi:10.1089/ 108497804323071931. PMid:15186596. (Pubitemid 38685114)
73. Vecchio S, Salvatore M. 99mTc-MIBI in the evaluation of breast cancer biology. Eur J Nucl Med 2004; 31: S88-96 doi:10.1007/s00259-004-1530-0. (Pubitemid 38833037)
74. Burak Z, Ersoy Ö, Moretti J-L, et al. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med 2001; 28: 1341-1350 doi:10.1007/s002590100588.
75. Kao C-H, Tsai S-C, Wang J-J, Ho Y-J, Ho S-T, Changlai S-P. Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors. Br J Haematol 2001; 113: 369-374 doi:10.1046/j.1365-2141.2001.02763.x. (Pubitemid 32523140)